International Journal of Hypertension / 2013 / Article / Tab 5

Clinical Study

Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT

Table 5

Gene associations with treatment resistant hypertension that are suggestive for both AA and white participants.

Variant name Rs number Geno-typeAfrican AmericanWhite
TRH casesControlsOdds ratio (95% CI)* value*TRH casesControlsOdds ratio (95% CI)* value*

CC717 (78.8)508 (72.7)564 (44.8)662 (40.9)
MTHFR1801133CT178 (19.6)175 (25.0)0.67
(0.52–0.86)
0.002555 (44.1)751 (46.4)0.88
(0.77–0.99)
0.04
TT15 (1.7)16 (2.3)139 (11.1)207 (12.8)

AA750 (82.3)553 (79.1)345 (27.6)502 (31.2)
MMP3 5A/6A3025058 *A153 (16.8)133 (19.0)0.75
(0.57–0.98)
0.04601 (48.1)778 (48.4)1.14
(1.01–1.29)
0.03
** 8 (0.9)13 (1.9)304 (24.3)327 (20.4)

GG842 (92.7)666 (95.0)1115 (88.7)1470 (91.0)
TNF361525GA63 (6.9)34 (4.9)1.87
(1.13–3.11)
0.02139 (11.1)143 (8.9)1.44
(1.10–1.90)
0.009
AA3 (0.3)1 (0.1)3 (0.2)2 (0.1)

Odds of being a case versus control for each copy of the minor allele (additive genetic model) after adjustment for age, sex, randomized treatment group, baseline values of BMI, HDL, eGFR, SBP, and DBP, smoking status, diabetes status, and history of LVH.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.